Nautilus Biotechnology Inc(NAUT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 6:21 AM ET (Korea 10/29 19:21)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.46 | Insider Own | 41.98% | Shs Outstand | 127.3M | Perf Week | 18.45% |
| Market Cap | 0.41B | Forward P/E | - | EPS next Y | - | Insider Trans | -8.56% | Shs Float | 73.8M | Perf Month | 135.16% |
| Enterprise Value | 0.35B | PEG | - | EPS next Q | -0.14 | Inst Own | 32.23% | Short Float | 7.61% | Perf Quarter | 211.65% |
| Income | -0.06B | P/S | 972.6 | EPS this Y | -3.19% | Inst Trans | 7.06% | Short Ratio | 1.15 | Perf Half Y | 28.4% |
| Sales | 0.00B | P/B | 3.51 | EPS next 5Y | 1.68% | ROA | -33.49% | Short Interest | 5.62M | Perf YTD | 64.62% |
| Book/sh | 0.92 | P/C | 4.72 | EPS past 3/5Y | -0.17% 0.21% | ROE | -41.01% | 52W High | -25.52% ($4.31) | Perf Year | 124.48% |
| Cash/sh | 0.68 | P/FCF | - | Sales past 3/5Y | - | ROIC | -42.1% | 52W Low | 281.64% ($0.84) | Perf 3Y | 33.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 7.31% | Gross Margin | -1242.22% | Volatility(W/M) | 28.13% 23.11% | Perf 5Y | -41.1% |
| Dividend TTM | - | EV/Sales | 830.12 | Sales Y/Y TTM | - | Oper. Margin | -15105.66% | ATR (14) | 0.43 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.25 | EPS Q/Q | -14.33% | Profit Margin | -13816.75% | RSI (14) | 66.73 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.25 | Sales Q/Q | - | SMA20 | 39.35% ($2.3) | Beta | 0.82 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/10/27 | SMA50 | 112.53% ($1.51) | Rel Volume | 3.1 | Prev Close | $2.89 |
| Employees | 130 | LT Debt/Eq | 0.19 | EPS/Sales Surpr. | 14.29% 13.43% | SMA200 | 52.33% ($2.11) | Avg Volume(3M) | 4.89M | Price | $3.21 |
| IPO | 2020/8/7 | Option/Short | Yes/Yes | Trades | 24652 | Volume | 15,145,125 | Change | 11.07% |
🧬 Nautilus Biotechnology (NAUT) is a US biotech company developing a next-generation platform that analyzes the proteome at the single-molecule level. Leveraging its proprietary Voyager instrument and Iterative Mapping technology, the company aims to accurately measure proteoforms that are difficult to detect using conventional approaches, and is currently in the pre-commercial development stage.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
Traded more than usual. That is 310% of its average volume.
NAUT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -3.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $97,260. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -41.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 32.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #238 of 594 in the industry
Based on market cap of $408M.
ZURA#237 Zura Bio Ltd $417M PER - NAUT#238 Nautilus Biotechnology Inc $408M PER - 
ALT#238 Altimmune Inc $408M PER - 
RZLT#240 Rezolute Inc $408M PER - 
TECX#241 Tectonic Therapeutic Inc $402M PER - 
FAQ
What kind of company is NAUT?
NAUT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NAUT?
The market cap of NAUT is approximately $408M, ranking 3,326 within its sector.
What is the 52-week high and low for NAUT?
NAUT has recorded a 52-week high of $4.31 and a low of $0.84.
